Eledon Pharmaceuticals (NASDAQ:ELDN) Releases Earnings Results, Misses Estimates By $0.32 EPS

Eledon Pharmaceuticals (NASDAQ:ELDN) announced its quarterly earnings results on Thursday. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.32), Zacks reports. During the same quarter in the previous year, the firm earned ($1.00) EPS.

Eledon Pharmaceuticals Stock Performance

NASDAQ ELDN traded up $0.03 during trading on Friday, hitting $3.47. The stock had a trading volume of 55,964 shares, compared to its average volume of 275,245. Eledon Pharmaceuticals has a one year low of $1.52 and a one year high of $5.54. The stock has a market capitalization of $207.35 million, a price-to-earnings ratio of -1.74 and a beta of 0.80. The stock has a 50 day simple moving average of $4.18 and a 200 day simple moving average of $3.85.

Analyst Upgrades and Downgrades

Separately, Guggenheim assumed coverage on Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They issued a “buy” rating and a $9.00 price target for the company.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).